Table 4:
Relapse of Inflammation in Patients with Juvenile Idiopathic Arthritis Associated Uveitis Attempting to Stop Immunomodulatory Therapy
| IMT | No. attempting stop | No. relapsing | % relapse | Median time to relapse, (days) | Time to relapse, (IQR) |
|---|---|---|---|---|---|
| Overall | 19 | 13 | 68 | 288 | 108–338 |
| Methotrexate | 12a | 7 | 58 | 336 | 329–636 |
| Mycophenolate mofetil | 2b | 0 | 0 | --- | --- |
| Cyclosporine | 4c | 1 | 25 | 213 | --- |
| Etanercept (Enbrel) | 1d | 0 | 0 | --- | --- |
| Adalimumab (Humira) | 2e | 1 | 50 | 344 | --- |
| Infliximab (Remicade) | 8f | 7 | 88 | 91 | 59–118 |
a
3 were combination therapies with mycophenolate, adalimumab, and cyclosporine
b
1 was on combination with infliximab.
c
3 were on combination with mycophenolate; methotrexate; and methotrexate and infliximab
d
0 were on combination therapy
e
1 was on combination with methotrexate
f
6 were on combination with methotrexate (4) and mycophenolate (2)